InCarda
is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cardiovascular diseases... Read moreInCarda
is a California-based biopharmaceutical company that researches and develops novel therapeutics for the treatment of cardiovascular diseases... Read more
News
Oct 01, 2024
OINDPnews
InCarda: InCarda says development of FlecIH-103 flecainide inhalation solution will continue despite early termination of Phase 3 trial
Sep 30, 2024
FinanzNachrichten
InCarda: InCarda Therapeutics, Inc.: InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development
Jun 12, 2023
Endpoints News
InCarda: InCarda terminates PhIII trial of its inhaled atrial fibrillation drug
Jan 21, 2023
InCarda Vimeo Channel
InCarda posted a video "Introducing InCarda's Orally Inhaled Flecainide for PAF Therapy" on VIMEO
Oct 04, 2022
GlobalNewswire
Press Release: InCarda : InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
Sep 23, 2022
Medical Product Outsourcing
InCarda: physIQ, InCardia Therapeutics Partner on Phase III Afib Study
Jul 26, 2022
OINDPnews
InCarda: InCarda Therapeutics initiates Phase 3 trial of InRhythm inhaled flecainide for atrial fibrillation
Jun 23, 2021
GlobalNewswire
Press Release: InCarda : InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm for Treatment of Atrial Fibrillation
Jun 15, 2021
FiercePharma
InCarda: InCarda posts midphase data on inhaled atrial fibrillation drug
Jun 09, 2021
Endpoints News
InCarda: With its eyes set on an IPO raise, InCarda preps to unroll mid-stage data backing inhaled arrhythmia drug
InCarda Competitors
1
2
3
4
5
6
7
8
9
10